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Discharge Abstract Database and National Ambulatory Care Reporting System 
database. All acute care hospitalization discharge abstracts with either conges-
tive heart failure (ICD-10 code I50.0) recorded as the most responsible diagnosis 
(MRDx) or contributing diagnosis amongst patients aged ≥ 18 were included in the 
study. Abstracts with a CHF MRDx were categorized in the CHF group. The remain-
ing abstracts were categorized into either the cardiovascular group (circulatory 
system disease MRDx (ICD-10 I00 – I99), excluding CHF) or non-cardiovascular 
group (non-circulatory system disease MRDx). Discharge abstracts with missing 
demographics, or absent without leave or against medical advice discharge sta-
tus were excluded. Results: 156,847; 66,056; and 127,847 CHF, cardiovascular, 
and non-cardiovascular group discharge abstracts were included, respectively, 
of which 10%, 13% and 21% of the respective group abstracts resulted in death. 
The national mean hospitalization visit cost was $10,123; $20,890; and $21,283 
for the CHF, cardiovascular, and non-cardiovascular groups respectively. For each 
CHF, cardiovascular, and non-cardiovascular group, a survival outcome incurred 
a lower national mean hospitalization visit cost at $9,222; $19,899; and $19,036 
whereas a death outcome incurred a high national mean hospitalization visit cost 
at $18,087; $27,642; and $29,887, respectively. ConClusions: Cardiovascular and 
non-cardiovascular hospitalizations result in higher mean hospitalization costs 
than those with a CHF MRDx. An opportunity exists for interventions reducing 
the number of any CHF related hospitalization to ease the burden on healthcare.
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objeCtives: Randomized clinical trials comparing percutaneous coronary inter-
ventions (PCI) and non-invasive treatment of acute coronary syndromes mostly 
favour the invasive approach. This study aimed at assessing whether in a real 
life setting PCI has an impact on outcomes as hospitalization cost, length of 
stay (LOS) and mortality in patients hospitalized for acute coronary syndromes 
(ACS) in Belgium. Methods: The hospitalization cost, average length of stay 
(LOS) and mortality among hospitalized patients with ACS were estimated using 
the longitudinal IMS Hospital Disease Database (year 2013), including data on 
about 24% of Belgian hospital beds. Stays were identified based on ICD-9 cod-
ing and split in ST-elevated Myocardial infarction (STEMI ICD-9: 410 excluding 
410.7), non-STEMI (NSTEMI: ICD-9: 410.7-411.89) and unstable angina (UA; ICD-9: 
411.1-411.8-413.0). PCIs were identified with ICD-9 code 36.0. Comparisons were 
performed using a Wilcoxon non-parametrical test for cost/ LOS and a Chi-square 
for mortality. Results: 2,528 STEMI, 2,815 NSTEMI and 407 UA hospitalizations 
were retrieved from the database, with respectively 1,457, 1,194 and 30 of them 
treated invasively. PCI resulted in higher costs in STEMI (€ 9,342 vs. € 8,165; p< 0.001) 
and UA (€ 9,186 vs. € 4,714; p< 0.001) and in lower costs in NSTEMI (€ 8,483 vs. € 9,483; 
p< 0.001). LOS of patients undergoing PCI was significantly lower in STEMI (6.2 
vs. 9.7 days; p< 0.001) and NSTEMI (5.6 vs. 10.9; p< 0.001). In-hospital mortality in 
patients with PCI was lower in both STEMI (6.2% vs. 21.4%; p< 0.001) and NSTEMI 
(1.6% vs. 8.0%; p< 0.001). LOS (5.5 vs. 5.9 days) and mortality (0.0% vs. 3.2%) were 
not significantly different in UA. ConClusions: Although information on the 
baseline characteristics of the different patients is limited, the findings of this 
retrospective study seem to support randomized clinical trials. Treatment with PCI 
significantly decreases the LOS and the mortality in patients with a myocardial 
infarction, at a limited marginal cost.
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objeCtives: To evaluate the costs and benefits of Yindanxintai dropping pills 
(Guizhou Junzhitang Pharmaceutical Company) for angina pectoris caused 
by coronary heart disease from the societal perspective. Methods: The com-
parator was chosen from published literature. Treatment results and costs were 
derived from published literature and government websites. A contingent valu-
ation survey was used to elicit the respondents’ willingness-to-pay (WTP) for 
angina pectoris treatments. The WTP was modeled as a function of the treat-
ment outcomes, design of questionnaire scenarios, individual health states and 
characteristics. A total of 351 questionnaires were completed. The primary out-
come was the annual net cost-benefit or incremental net cost-benefit per person 
tested. Results: WTP increased with the growth of effective rate. The average 
WTP was given 377 RMB per month (range 100 RMB to 2000 RMB) to the treatment 
with a 95% effective rate. There were 7 papers that provided adequate information 
to the further cost-benefit analysis (CBA). Results from the CBA indicated that 
Yindanxintai dropping pills had a positive annual net benefit when used alone, 
and the treatment with 56 days was superior to 28 days with an annual incre-
mental net benefit (AINB) of 4529 RMB per person tested. Yindanxintai dropping 
pills used with nitroglycerin tablets (Shanghai Sina Pharmaceutical Company) 
had greater net benefit than simvastatin tablets (Yangtze River Pharmaceutical 
Group) with nitroglycerin tablets (AINB= 1471 RMB). Yindanxintai dropping pills 
used with isosorbide mononitrate sustained release tablets (AstraZeneca AB), 
Xinkang tablets (Lunan Pharmaceutical Company), or Xinkang tablets and Xinke 
tablets (Guangzhou Nanxin Pharmaceutical Company) also had greater net ben-
efit than the other drugs used alone (AINB were 306 RMB, 479 RMB, 1067 RMB, 
respectively). The results of this research were proved robust through sensitivity 
analyses. ConClusions: Yindanxintai dropping pills is cost-beneficial in the 
treatment of angina pectoris caused by coronary heart disease either used alone 
or used with other drugs.
clinical course of DVT may also be complicated by recurrent episodes of DVT, the 
development of post-thrombotic syndrome (PTS), as well as chronic thromboem-
bolic pulmonary hypertension (CTEPH). The aim of study was to estimate the cost 
of VTE treatment in Turkey. Methods: The study was undertaken from the Turkish 
health care payer perspective. (SSI). An Excel sheet was formed to determine the 
healthcare resources used in treatment of VTE. VTE treatment costs were divided 
by anticoagulant use, monitoring INR, recurrent DVT, recurrent PE, non IC major 
bleeding (GIS), Intracranial bleed, CTEPH and PTS long term costs.Resource utiliza-
tion data were obtained via expert clinical views and included diagnosis costs and 
treatment costs. Unit costs were taken from the Social Security Institution’s Health 
Implementation Guideline. Results: According to the results of the study,cost 
ofanticoagulans were146,59 TL, monitoring INR costs were 90,00 TL, recurrent DVT 
costs were 1.972,41 TL, recurrent PE costs were 830,49 TL, non IC major bleeding 
(GIS) costs were 1.482,49, Intracranial bleed costs were 3.868,86 TL, CTEPH costs were 
22.228,12 TL and PTS long term costs were 754,29 TL in Turkey. ConClusions: The 
study showed that VTE treatment poses a high treatment cost due to recurrence 
and OAC complications in the Turkish health care system.
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objeCtives: Vietnam spends 6% of its GDP to health care. In context of insuf-
ficient evidence on quantifying the economic burden of cardiovascular disease in 
Vietnam, we conducted a study on the costs of Acute Myocardial Infarction (AMI). 
Costs were identified from the perspective of the health care payers, including 
health insurance providers and patients. Methods: Data was extracted from the 
database of a regional hospital in Vietnam. All patients with the single code I21 
according to the International Clarification of Disease 10 were included in the study. 
Costs were calculated in year 2013. Out-of-pockets payment was quantified as the 
net of health insurance (HI) reimbursement and actual payments. Results: 89 
patient-hospitalizations were included in the study, including 34 cases requiring 
percutaneous coronary intervention and 55 cases requiring medicine only. Mean 
costs of AMI were US$ 2,503 (+/-3,377) per hospitalization. Costs per hospitalization 
were higher in the group requiring percutaneous coronary intervention than in the 
group requiring medicine only at US$5,962 (+/- 3,197) and US$365 (+/- 401), respec-
tively. Out-of-pocket payments were approximately 60% of these costs. Generally, 
cost of AMI per hospitalization in Vietnam was higher than GDP per capita (US$ 
1,900). ConClusions: Our results indicate that MI prevention is needed to reduce 
the burden of disease as well as to avoid catastrophic expenditure and impoverish-
ment problemsin Vietnam. Our results also comprise essential building blocks for 
important variables in a future cost-effectiveness modeling exercise on cardiovas-
cular prevention.
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objeCtives: to compare the total treatment duration cost per patient between the 
two most used low-molecular-weight heparins (LMWHs) in Spain for the prophy-
laxis of the venous thromboembolism disease (VTE) and the treatment of deep 
vein thrombosis (DVT) with and without pulmonary embolism (EP), during the 
acute phase and at long term. Methods: patients in prophylaxis were classified 
as moderate or high according to the risk of the surgery. Patients with high risk 
were further classified by surgery type: 1) orthopedic or oncologic surgery, 2) other 
surgeries, and 3) medical patients (surgery is not performed by a surgical speciality 
but other specialists). Patients with DVT were divided into 10 kilogramme weight 
ranges as well as considering the distribution of the Spanish population in each 
range taken from the RIETE registry. Treatment duration was obtained from clini-
cal guidelines. Treatment duration and patient profile defined the strength and 
package size used to estimate the cost per patient in prophylaxis. Concerning 
DVT, only the most appropriate strengths for each weight range were considered. 
Costs are expressed in € of 2015 and calculated based on the retail price plus the 
value-added tax of each LMWH discounting the corresponding deduction accord-
ing to Royal Decrees. Results: administering enoxaparine instead of bemiparine 
represents a saving of 6€ (5%), 7€ (16%) and 7€ (16%) per patient per total treatment 
duration with high risk undergoing surgery type 1, 2 and 3, respectively, and 4€ 
(16%) per patient per total treatment duration with moderate risk. Average sav-
ings per patient per total treatment duration with DVT came to 61€ (56%) and 
354€ (46%) in the acute phase and at long term, respectively. ConClusions: the 
cost of treating VTE or DVT is lower when administering enoxaparine instead of 
bemiparine. Therefore, the use of enoxaparine represents an economic benefit 
for the Spanish health system.
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objeCtives: Chronic heart failure (CHF) affects more than 600,000 Canadians, 
resulting in thousands of hospitalizations and deaths each year. This study’s objec-
tive is to compare the mean cost ($CAD) of a CHF, cardiovascular, and non-cardi-
ovascular diagnosed hospitalization amongst acute care treated CHF diagnosed 
patients. This study builds upon previously presented Canadian CHF hospitaliza-
tion costing research. Methods: Hospital discharge abstracts recorded between 
2009 and 2013 were extracted from the Canadian Institute for Health Information’s 
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compared to the anticoagulants it had the highest incremental net monetary benefit 
compared with warfarin; £596 (£-6,494 to £4,524). This was due to the low cost and 
risk of adverse events of aspirin. All other comparators had a negative incremental 
net monetary benefit compared with warfarin. ConClusions: For acute treatment, 
apixaban had the highest probability (57%) of being cost-effective at a willingness to 
pay threshold of £20,000 for acute treatment. Novel oral anticoagulants are unlikely 
to be cost-effective for long term use in secondary prevention.
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objeCtives: Worldwide, stroke is the third most common cause of death in devel-
oped countries with declining death rates. In Austria the incidence rate of stroke 
is 2.1 – 2.3 per thousand annually. Cerebrolysin prevents acute neuronal damage 
and accelerates recovery after stroke. The purpose of this analysis was to deter-
mine costs of stroke for Austria in general and to estimate the cost-effectiveness 
of Cerebrolysin in combination with alteplase compared to alteplase alone. The 
analysis should assess health economic advantages in the acute care due to a faster 
improvement in neurological impairment and for rehabilitation in early post-acute 
phase and quantify the correlated reduced resource use in the health care and 
social system. Methods: A Markov-model was developed based on the mRS 
states 90 days after stroke to simulate consequences over a 10-year time-horizon. 
Consequences include recurrent stoke, deteriorated mRS, death due to recurrent 
stroke or other reasons. Health benefits were measured in quality-adjusted life years 
(QALYs) and life years (LYs). Monte-Carlo-simulation accounted for uncertainty. 
Probabilities were derived from RCTs and open-label studies; direct costs (2014) 
were derived from published sources from the payer’s perspective. QALYs, life years 
and costs were projected over a 10 year time-horizon. Costs and outcomes were 
discounted according to the national guidelines Results: Austrian costs associated 
with Cerebrolysin amount to € 61,468.67 and generate 3.77 QALYs and 6.70 LYs. Costs 
without Cerebrolysin amount to € 62,257.88, achieve 3.75 QALYs and 6.70 LYs. The 
treatment strategy with Cerebrolysin dominates the strategy without Cerebrolysin. 
Assessing the disaggregated costs it becomes apparent that costs savings are due to 
lower acute stroke costs (€ -493.29) and nursing-home costs mainly after first stroke 
(€ -250.88). ConClusions: From a health economic perspective, Cerebrolysin is a 
cost-effective therapy; it mainly reduces event costs due to early remobilization 
and, in addition, rehabilitation and nursing-home cost.
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objeCtives: A novel pharmacist guided pharmacogenetic service (PGx) for patients 
newly started on warfarin has been implemented at the University of Illinois 
Hospital & Health Science System (UI-Health). Although the PGx service was found 
to be more effective in reducing bleeding and thrombosis related hospitalizations 
at 90 days post warfarin initiation compared to usual care, the cost of the genotype 
test and the PGx consult service warrants economic evaluation beyond 90-days 
of follow-up. The objective of this study was to evaluate the long-term cost-effec-
tiveness of this novel pharmacist guided warfarin PGx service compared to usual 
care. Methods: A cost-effectiveness model was developed in TreeAge Pro 2014, 
Williamstown, MA, USA. Patients in either the PGx or the usual care cohort followed 
by UI-health were included as comparators and costs and QALYs were estimated 
over a 5 year horizon. Warfarin related (i.e., bleeding or thrombosis) readmissions 
at 30 and 90 days were modeled in a decision tree. Patients in the model without 
a fatal event within 90 days transitioned to a Markov model with a 3-month cycle. 
For patients with venous thromboembolism, the Markov states included well, post 
intracranial hemorrhage (ICH), post thrombotic syndrome, and dead, whereas those 
with atrial fibrillation included well, post ICH, post stroke, post myocardial infarc-
tion and dead. Utilities, cost inputs and transition probabilities were taken from the 
literature and an annual 3% discount rate was used. Results: At 5 years, patients 
managed by the PGx service had expected costs of $7412 and gains of 4.41 QALYs 
whereas those who received usual care had expected costs of $7926 and gains of 
4.39 QALYs. ConClusions: A novel pharmacist guided warfarin pharmacogenetic 
service was projected to be cost-saving and to result in similar or higher QALYs by 
reducing hospitalizations due to warfarin related adverse events.
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objeCtives: To assess the cost-effectiveness of edoxaban versus standard ther-
apy (low molecular weight heparin overlapped and followed by acenocoumarol) 
in patients with venous thromboembolism (VTE), including deep vein thrombosis 
(DVT) and pulmonary embolism (PE). Methods: A Markov model was developed 
to describe the management and consequences of VTE for Spain. We defined a 
cycle’s length of 2 weeks and different health states to simulate the natural history 
of VTE patients after suffering DVT and/or PE. Patients were treated with edoxaban 
or standard therapy for 3, 6 and 12 months, 12 month treatment period being our 
base case scenario. We used the HOKUSAI study and related literature to obtain 
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objeCtives: To evaluate the cost-effectiveness of using levosimendan compared 
with dobutamine, in the perioperative treatment of patients undergoing cardiac 
surgery who require inotropic support. Methods: A two-part Markov model was 
designed to simulate health state transitions of patients undergoing cardiac sur-
gery, and estimate the short- and long-term health benefits of treatment. Hospital 
length of stay (LOS), mortality, medication and adverse events were key clinical 
and cost inputs. Treatment cost-effectiveness was evaluated in terms of costs, 
incremental cost per Life Years (LYs), and incremental cost per Quality-Adjusted 
Life Years (QALYs) gained within the German healthcare system. Drug prices were 
calculated from the German Drug Directory (€ /2014) and published literature, with 
a 3% yearly discount rate applied. The base case analysis was for a one year time 
horizon. Results: The use of levosimendan versus dobutamine was associated 
with cost savings of € 4787 per patient from the German hospital perspective. These 
cost savings were due to reduced adverse events and shorter hospital LOS, lead-
ing to increased bed capacity and hospital revenue. Excluding revenue gains, the 
incremental cost per LY was € 9115 and incremental cost per QALY was € 11,919 
for levosimendan versus dobutamine. Levosimendan was 95% to 100% likely to 
be cost-effective at a willingness to pay threshold of € 20,000 to € 40,000 per QALY. 
Probabilistic sensitivity analyses demonstrated that results were robust to param-
eter changes. ConClusions: The use of levosimendan in patients undergoing 
cardiac surgery who require inotropic support is cost-effective and potentially 
cost-saving compared with dobutamine.
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objeCtives: Thyroid function testing during amiodarone therapy is recommended 
every 6 months in order to control for the risk of hypothyroidism and thyrotoxicity, 
although evidence of the effect of regular monitoring on the risk of amiodarone-
related ADEs, cost and utility is sparse. This study investigated the cost-effectiveness 
of alternative frequency of monitoring amiodarone therapy in UK general prac-
tice. Methods: A cost-effectiveness analysis compared alterative frequency of 
monitoring (once in 6 months (recommended frequency), less than once in 6 months 
(less frequent), more than once in 6 months (more frequent)). A Markov model with 
cycle length of 90 days and 5 year horizon simulated progression through the ADE 
pathway (hypothyroidism, thyrotoxicity, cardiac complications). Treatment effect 
of monitoring on risk of ADE was estimated from UK GP and hospital observational 
data. Propensity score weights were used to control for non-random assignment. 
Probabilities, utilities and costs were derived from literature on amiodarone-related 
toxicity, with priority given to UK based-studies. Cost and utility was assessed from 
the perspective of NHS England and discounted at 3.5% per annum. A probabil-
istic sensitivity analysis (PSA) estimated the effect of parametric uncertainty on 
incremental cost and effect. Results: Recommended frequency monitoring was 
the dominant strategy. Mean incremental QALYs: 0.036 (95%CI -0.066,0.075), 0.039 
(-0.068,0.085); mean additional cost: -£6 (-283,272), -£61 (-360,238) vs. less frequent 
and more frequent monitoring, respectively. However, due to small differences in 
QALY and cost generated and significant uncertainty in model parameters, the prob-
ability of cost-effectiveness was 41% at £20,000/QALY threshold. ConClusions: 
The analysis supported the current recommendation for 6-monthly monitoring of 
thyroid function in amiodarone therapy, although the confidence in this conclusion 
was low due to poor evidence on the risk of amiodarone-related thyroid ADEs and 
their economic effect. Additional investigation of amiodarone monitoring is needed 
in order to justify its application in primary care.
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objeCtives: This study estimated the cost-effectiveness of novel oral anticoagu-
lants for (i) acute treatment and (ii) secondary prevention, of VTE from the perspec-
tive of the NHS. Methods: Secondary prevention:A Markov model was developed 
to evaluate cost-effectiveness of aspirin, rivaroxaban, dabigatran, warfarin (INR 2-3), 
apixaban 2.5mg and apixaban 5mg, compared to “no pharmacotherapy”. Acute treat-
ment: A decision tree model for short term outcomes, followed by the secondary pre-
vention model for long-term consequences, was used to evaluate cost-effectiveness 
of dabigatran, rivaroxaban, apixaban and edoxaban, compared with warfarin (INR 
2-3). All interventions were considered at the licensed dose(s). Efficacy and safety 
parameters were informed by network meta-analyses and longitudinal studies were 
used to parameterise the long term follow up. The models had a life time horizon 
with costs and QALYs discounted at 3.5%. Results: All results are presented at a 
£20,000 willingness to pay per QALY threshold Acute treatment:Apixaban showed 
the highest expected QALYs (12.02) and was the most cost-effective intervention 
with an incremental net monetary benefit of £645 (£-1,274 to £2,100) compared to 
Warfarin. Rivaroxaban also had a positive incremental net benefit (£167); all other 
comparators had a negative incremental net monetary benefit compared with war-
farin. Secondary prevention:Although aspirin has a higher risk of recurrent VTE 
